CURRICULUM VITAE - Renata Schoemanrenataschoeman.co.za/wp-content/uploads/2014/07/RenataCV.pdf · July 2014 1 CURRICULUM VITAE PERSONAL DETAILS Name: Renata Schoeman CURRENT POSITION

July 2014

1

CURRICULUM VITAE

PERSONAL DETAILS

Name: Renata Schoeman

CURRENT POSITION

2008+ Full time Private Practice

2011+ Researcher, Department of Chemical Pathology, University of Stellenbosch

2013+ MBA student, University of Stellenbosch Business School

2013+ Member of the USB-ED virtual faculty for Neuroleadership programmes

WORK EXPERIENCE

2000 Internship (Universitas/Pelonomi/National Complex)

2001 Community Service (Pelonomi/Botshabelo/Marokka Complex)

2002 Medical Officer (Dept Family Medicine, National Hospital, Bloemfontein)

2003-2006 Registrar Psychiatry (University of Stellenbosch, Dept of Health,

PAWC Lentegeur Hospital)

2007-2008 Research Fellow/Consultant (Dept of Psychiatry, University of

Stellenbosch

Extraordinary lecturer, Dept of Psychiatry, University of Stellenbosch

External lecturer, Neuroanatomy, Dept of Anatomy and Histology,

University of Stellenbosch

External lecturer, Clinical Neurology (Developed Clinical Neurology

curriculum for Speech and Language Therapists), Department of

Anatomy and Histology, University of Stellenbosch

Limited Private Practice

2008 Examiner: Colleges of Medicine of South Africa, Psychiatry (Part 1)

Examiner MMed Psychiatry Neurophysiology

July 2014

2

2009-2010 External lecturer, Department of Psychology, University of Stellenbosch

(Developed Brain Behaviour Module for Honors level students)

2009-2013 Sub-investigator Cape Trial Centre (Principal investigator: Juan

Schronen)

2009-2012 Member of the Health Research Ethics Committee, Faculty of Health

Sciences, University of Stellenbosch

QUALIFICATIONS

1993 Matriculated (C&N Secondary Girls’ School Oranje)

1999 MBChB (University of the Free State)

2001 BSocSc (Hons) (Psychology) (Cum Laude) (University of the Free State)

Diploma in Mental Health (SA) (Colleges of Medicine of South Africa)

Psychometrist registration examination, Professional Board of Psychology,

HPCSA

2002 MSocSc (Psychology) (University of the Free State)

2006 FCPsych (Colleges of Medicine of South Africa) (Cum Laude)

MMed (University of Stellenbosch) (Cum Laude)

2011 PhD

AWARDS

1993 Dux- pupil (C&N Secondary Girls’ School Oranje)

Image-builder of the year (C&N Secondary Girls’ School Oranje)

Best Cultural achievements (C&N Secondary Girls’ School Oranje)

Presidentsverkenner (‘Voortrekker’ Medal of Honour for exceptional

leadership)

Awards for “Best all-rounder” and “Best personal achievements” in “Die

Volksblad” and University of the Free State’s “Matriculant of the year”

1996-1999 Naspers-bursary

1997 JA Olivier- award for the best student in Forensic Medicine

July 2014

3

1998 Helmut Schimff- award for the best student in Othorhinolaringology

1999 Bristol- Myers Squibb- award for the student with the best achievement in

Psychiatry over all the years of study

2002 Awarded Academic Colours from the Student Council, University of the

Free State for exceptional achievement in the degree

BSocSc(Hons)(Psychology)

Awarded Dean’s medal for the best honours student in the Faculty of

Social Sciences, University of the Free State

Receives Kovsie Alumni Trust award as the best honours student in the

Faculty of Social Sciences, University of the Free State

Awarded National Research Foundation bursary

2005 Best Poster presentation by registrar, Neuroscience, Academic Year Day,


2006-2009 Thuthuka award, National Research Foundation

2007-2008 Medical Research Council Research Fellowship

2007-2008 Discovery Foundation Academic Fellowshiip

2007-2008 Harry Crossley Foundation Award

2007 Novartis medal for best results in Fellowship examination of the College of

Psychiatrists of South Africa, 2006

2008 Clinical Research Fellowship, Faculty of Health Sciences, University

Stellenbosch

American Psychiatric Association/AstraZeneca Young Minds in Psychiatry

Award, Washington, USA

Award for the best “Under 35 year” presentation in Neuroscience, Annual

Academic Yearday, Universtiy of Stellenbosch

2009 Included in the Marquis’ “Who’s who in the world”

2012 2nd price for Poster presentation, Neuroscience, Academic Year Day,


July 2014

4

COURSES/CONGRESSES ATTENDED

1994 South Sotho course (Bloemfontein Technical College)

2002 American Heart Association for the Basic Life Support for Healthcare

Providers Program (BLS)

American Heart Association for the Advanced Cardiovascular Life Support

Program (ACLS)

American Heart Association for the Pediatric Advanced Life Support

Program (PALS)

Co-presenter: Forensic Medicine and Pathology Refresher Course, for the

Department of Health, Eastern Cape

2004 Advanced Certificate in Electro Convulsive Therapy (South African

Society of Psychiatrists)

Narrative Therapy Workshop

Co-Presenter of Neurodevelopmental workshop, Dept Anatomy, University

Stellenbosch

Investigator Research Course (Foundation for Professional Development)

Evidence-based Practice and Cochrane Collaboration Workshop (SA

Cochrane Centre)

SASOP (South African Society of Psychiatrists) Congress

2005 Medical Ethics Course, Foundation for Professional Development (Cum

Laude)

CINP Congress

2006 South African Neuropsychology Association (SACNA) Congress

SASOP Congress

2007 Biological Psychiatry Congress, University of Stellenbosch

Workshop: Introduction to principles and processes of Research, University of

Stellenbosch

World Federation of Societies of Biological Psychiatry Congress, Chile

Training visit (Matrics Consensus Cognitive Battery, MGH, Boston, MA

Investigator Training Program (GCP), Phizer

July 2014

5

“Writing for Scientific Publication” workshop, Division of Research

Development, University of Stellenbosch

IRENSA (International Research Ethics in Southern Africa) Seminar

MGH/MIT/HMS AA Martinos Center for Biomedical Imaging Visiting

Fellowship Program, Boston, MA

2008 Training visit (Statistical Parametric Mapping) to Institute of Psychiatry, King’s

College, January 2008

APA Research Colloquium for Junior Investigators, May 2008, Washington,

USA

APA (American Psychiatric Organization) Congress, May 2008, Washinton,

USA

Fine Health Care Medical Workshop, Adult ADHD, Oct 2008, Cape Town,

RSA

Local Lundbeck Institute: Sharing Reponsibilities for Improved Care, Nov

2008, Johannesburg, RSA

Lundbeck Institute: Clinical trial meeting (Kopenhagen, Denmark)

2009 APA Congress, May 2009, San Francisco, USA

SASOP Biological Psychiatry Congress, May 2009, Kleinmond, South Africa

ECNP, September 2009, Istanbul, Turkey

2010 CINP Course in Psychopharmacology

ERECCA Good Clinical Practice course, University of Stellenbosch

Evidence-Based Psychiatry, Lundbeck Institute, Sept 2010, Johannesburg,

RSA

SASOP Neuropscyhiatry Symposium, August 2010, Cape Town, South Africa

2011 SASOP Psychiatry Symposium, March 2011, Cape Town, RSA

Lilly Neuroscience day, May 2011, Cape Town, RSA

Invited speaker, Lundbeck “Mad Hatter’s Tea Party”, June 2011, Cape Town,

South Africa

Invited speaker, CPC/Qualicare Open Day, July 2011, Cape Town, South

Africa

ECNP, September 2011, Paris, France

July 2014

6

Examiner’s workshop: Standard Setting, CMSA, Cape Town, South Africa

2012 CINP, June 2012, Stockholm, Sweden

Masterson’s Institute for Psychoanalytic Psychotherapy, August 2012, Cape

Town, South Africa

Tiny Handz (sign language)

2013 Invited speaker, Psychiatric Management Group, May 2013, Cape Town,

South Africa

Co-presenter, Neuroleadership, June 2013, Cape Town, South Africa

Invited speaker, Alzheimer’s South Africa, September 2013, Somerset West,

Cape Town, South Africa

ECNP, October 2013, Barcelona, Spain

ERECCA Good Clinical Practice course, University of Stellenbosch

2014 Co-presenter: Neuroscience of negotiation and mediation, USB-ED

Co-presenter: Neuroscience of managing differences, UCT-ED

PUBLICATIONS IN PEER REVIEWED JOURNALS

Schoeman R & Louw DA (2003). Neuropsychological Assessment versus Neuro-

imaging in the Diagnosis of Cerebral Lesions: An Explorative Study. Medical

Technology SA, 17(1), 386-393.

Louw DA & Schoeman R (2003). Moderator Variables in Neuropsychological

Assessment. Medical Technology SA, 17(2), 407-413.

Leppanen JM, Niehaus DJ, Koen L, Du Toit E, Schoeman R & Emsley R (2006).

Emotional face processing deficit in schizophrenia: a replication study in a South

African Xhosa Population. Schizophrenia Research, 84(2-3), 323-330.

Lochner C, Hemmings S, Seedat S, Kinnear C, Schoeman R, Annerbrink K, Olsson

M, Eriksson E, Moolman-Smook J, Allgulander C, Stein DJ. (2007). Genetics and

July 2014

7

personality traits in patients with social anxiety disorder: A case-control study in

South Africa. Eur Neuropsychopharmacol, 17(5), 321-327.

Leppanen JM, Niehaus DJ, Koen L, Du Toit E, Schoeman R & Emsley (2008).

Deficits in facial affect recognition in unaffected siblings of Xhosa schizophrenia

patients: Evidence for a neurocognitive endophenotype.

Schizophrenia Research. 99(1-3):270-3.

Emsley R, Chiliza B & Schoeman R. (2008). Predictors of long-term outcome in

schizophrenia. Curr Opin Psychiatry, 21(2):173-7.

Schoeman R, Southwood F, Chiliza B & Emsley R (2008). Bilingualism and

psychosis: a case report. Schizophrenia research, 103(1-3), 333-335.

Abubaker R, Alaerts M, Allman AA, Barnett J, Belujon P, Bittner RA, Burne TH, Cahn

W, Chance S, Cherkerzian S, Desouza R, Di Forti M, du Bois T, Fatjó-Vilas M,

Green M, Halpern D, John JP, Kemp A, Koelkebeck K, Lee J, Lodge DJ,

Michalopoulou P, Mompremier L, Nelson B, Perälä J, Rotarska-Jagiela A, Schoeman

R, Thakkar KN, Valuri G, Varambally S, Zai C, Delisi LE (2008). Summary of the 1st

Schizophrenia International Research Society Conference oral sessions, Venice,

Italy, June 21-25, 2008: The rapporteur reports. Schizophrenia Research. Oct;

105(1-3):289-383. Epub 2008 Sep 26

Leppanen JM, Niehaus DJ, Koen L, Schoeman R, Emsley R (2008). Allocation of

attention to the eye and mouth region of faces in schizophrenia patients. Cognitive

Neuropsychiatry, 13(6), 505-519.

Southwood F, Schoeman R & Emsley R (2009). Bilingualism and psychosis: A

linguistic analysis of a patient with differential symptom severity across languages.

Southern African Linguistics and Applied Language Studies, 27(2):163-171

July 2014

8

Schoeman R, Carey P, Seedat S (2009) Trauma and Posttraumatic Stress Disorder

in South African Adolescents: A case-control study of cognitive deficits. Journal of

Nervous and Mental Disease, 197(4):244-50.

Hoare J, Fouche J-P, Spottiswoode B, Joska JA, Schoeman R, Stein DJ & Carey PD

(2010). White matter correlates of apathy in HIV-positive subjects: a diffusion tensor

imaging study. J Neuropsychiatry Clin Neurosci, 22:313-320.

Schoeman R & Van der Merwe G (2010). Aphasia, an acquired language disorder.

SA Fam Pract, 52(4):308-311

Smit M, Conradie S & Schoeman R (2011). A grammatical analysis of the

spontaneous L2 English use of schizophrenic bilinguals compared to typical

bilinguals. Southern African Linguistics and Applied Language Studies, 29(4), 505-

513.

Theron J, Conradie S & Schoeman R (2011). Pragmatic assessment of

schizophrenic bilinguals' L1 and L2 use. Southern African Linguistics and Applied

Language Studies, 29(4):515-531.

Lachman A, Cloete KJ, Kidd M & Schoeman R (2012). The Clinical Utility and Cost

Effectiveness of Routine Thyroid Screening in Adult Psychiatric Patients Presenting

at Stikland Hospital, Cape Town, South Africa. African Journal of Psychiatry, 15:36-

41.

Delport, D, Schoeman R, Geiger, D & Kotza, M (2013). Significance of dietary folate

intake, homocysteine levels and MTHFR 677 C>T genotyping in South African

patients diagnosed with depression: Test development for clinical application

Metabolic Brain Disease. Neuroscience in Africa (in print).

July 2014

9

CHAPTERS

Schoeman R, Niehaus DJH, Koen L & Leppanen JM (2008) Emotion recognition

deficits as a neurocognitive marker of Schizophrenia liability. In MS Ritsner (Ed)

Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, advances,

and challenges. Springer (2009)

CONGRESS CONTRIBUTIONS/ PUBLIC PRESENTATIONS

Invited speaker at many different CME/CPD activities for psychiatrists, general

practitioners, allied health professionals, pharmacists, and also for the general

public.

Schoeman R, Lochner C, Moolman-Smook H, Hemmings S, Kinnear C,

Allgulander C, Seedat S & Stein D (2005). The Genetics of Social Anxiety

Disorder. Poster presentation at CINP Regional Meeting, Cape Town, RSA.



Disorder. Poster presentation the International Anxiety Disorder Congress, Cape

Town, RSA



Disorder. Best Poster presentation by registrar, Neuroscience, Academic Year

Day, University of Stellenbosch.

Schoeman R, Middleton T, Jordaan I, Carey P & Seedat S (2007).

Neuropsychological functioning in traumatised adolescents with and without

PTSD. Poster presentation at the Biological Psychiatry Congress, Cape Town,

RSA.

July 2014

10

Schoeman R, Middleton T, Jordaan I, Carey P & Seedat S (2007).

Neuropsychological functioning in traumatised adolescents with and without

PTSD. Poster presentation at the World Federation of Biological Psychiatry

Congress, Santiago de Chile


Psychosis: a case report. Poster presentation at the Annual Academic Year Day,

University of Stellenbosch.

Schoeman R, Conradie S & Emsley R (2008). Differential expression of psychotic

features in late bilinguals: an fMRI study. Poster presentation at the American

Psychiatric Association Congress, Washington DC

Schoeman R, Chiliza B & Emsley R (2008). Early cognitive response to treatment in

First Episode Psychosis. Poster presentation at the American Psychiatric

Association Congress, Washington DC


features in late bilinguals: an fMRI study. Oral presentation at the American

Psychiatric Association Research Colloquium for Junior Investigators, Washington

DC

Chiliza B, Schoeman R, Emsley R, Oosthuizen P, Niehaus D, Koen L & Hawkridge S

(2008). Treatment of first-episode psychosis: efficacy and tolerability of a long-acting

typical antipsychotic. Poster presentation at Schizophrenia International Research

Society Conference, Venice, Italy


psychosis: a case report. Poster presentation at Schizophrenia International

Research Society Conference, Venice, Italy

July 2014

11

Schoeman R, Chiliza C, Emsley R (2008). Early cognitive response to treatment in

first episode psychosis. Poster presentation at Schizophrenia International Research


Focking M, Schoeman R, Dickers P, Hudson L, Dunn M & David R (2008).

Proteomic and Western blot analysis of hippocampal subregions in schizophrenia

and bipolar disorders. Poster presentation at Schizophrenia International Research


Chiliza B, Schoeman R, Emsley R, Oosthuizen P, Niehaus D, Koen L &

Hawkridge S (2008). Treatment of first-episode psychosis: efficacy and tolerability

of a long-acting typical antipsychotic. Poster presentation at Annual Academic

Year Day, Faculty of Health Sciences, University of Stellenbosch.

Du Toit, E, Niehaus DJH, Koen L, Schoeman R & Emsley R (2008). Emotional

face processing deficit in schizophrenia: a repliucation study in a South African

Xhosa population. Oral presentation at Annual Academic Year Day, Faculty of

Health Sciences, University of Stellenbosch.


features in late bilinguals: an fMRI study. Poster presentation at Annual Academic

Year Day, Faculty of Health Sciences, University of Stellenbosch.

Schoeman R, Chiliza C, Emsley R (2008). Early cognitive response to treatment in

first episode psychosis. Oral presentation at Annual Academic Yearday, Faculty of

Health Sciences, University of Stellenbosch. Award for the best “Under 35”

presentation in Neuroscience.

July 2014

12


features in late bilinguals: an fMRI study. Special lecture, Dept of Psychology,

University of Stellenbosch.

Schoeman R & Verster,C (2009). Selective Serotonin Reuptake Inhibitors: The effect

on Haemostasis (2009). Oral presentation at the SASOP Biological Psychiatry

Congress, Kleinmond, South Africa

Chiliza B, Schoeman R, Oosthuizen P, Koen L, Niehaus D, Emsley R.

Methamphetamine use and first episode psychosis in Cape Town. Oral presentation

at the South African Society of Psychiatrists Biological Psychiatry Congress, May

2009.

Chiliza B, Schoeman R, Oosthuizen P, Koen L, Niehaus D, Emsley R.

Characteristics of first episode psychosis patients with a history of

methamphetamine use. Poster presentation at the 10th Annual Meeting of the

International Society of Addiction Medicine, Cape Town, South Africa, November

2008.

Chiliza B, Schoeman R, Oosthuizen P, Koen L, Niehaus D, Hawkridge S, Emsley R.

Treatment of first-episode psychosis: efficacy and tolerability of a long-acting typical

antipsychotic. Poster presentation at the 6th International Conference on Early

Psychosis, Melbourne, Australia, October 2008.

Chiliza B, Schoeman R, Oosthuizen P, Koen L, Niehaus D, Hawkridge S, Emsley R.

Treatment of first-episode psychosis: efficacy and tolerability of a long-acting typical

antipsychotic. Oral presentation at the 15th National Congress of the South African

Society of Psychiatrists, August 2008.

Schoeman R, Oosthuizen P, Kidd M & Emsley R (2009). Social cogntion: Response

to treatment in first episode psychosis. ECNP, Turkey

July 2014

13

Conradie S & Schoeman R (2009). Linguistic analysis of schizophrenic speech in

bilinguals. LSSA, Cape Town

Davis W, de Kock L, Pretorius K, Schoeman R, van Rensburg SJ & Kotze MJ

(2011). Development of a single nucleotide polymorphism (SNP) knowledge

database: ASMT RS4446909, RSS598968 and MTHFR RS1801133 as susceptibility

alleles for depression. Biological Psychiatry Congress, Stellenbosch, South Africa.

Conradie S, Smit M, Theron J & Schoeman R (2012). Grammatical and pragmatic

analysis of the L1 and L2 use of schizophrenic bilinguals . International Second

Language Research Forum, Pittsburgh, USA

Schoeman R, Lachman A, Cloete KJ & Kidd M (2012). The clinical utility and cost

effectiveness of routine thyroid screening in adult psychiatric patients presenting

at Stikland Hospital, Cape Town, South Africa. Poster presentation at Annual

Academic Year Day, Faculty of Health Sciences, University of Stellenbosch.

Schoeman R, Lachman A, Cloete KJ & Kidd M (2013). The clinical utility and cost

effectiveness of routine thyroid screening in adult psychiatric patients presenting

at Stikland Hospital, Cape Town, South Africa. Poster presentation at European

College of Neuropsychopharmacology Congress, Barcelona, Spain.

RESEARCH EXPERIENCE

PhD: “A prospective study of cognitive deficits in First Episode Psychosis, and the

response thereof to treatment with Flupenthixol decanoate” (supervisor: Piet

Oosthuizen)

MMed thesis: “A Neuropsychological comparison between traumatized

adolescents with and without PTSD (supervisor: Soraya Seedat)

July 2014

14

MSocSc thesis: “Neuropsychological Assessment versus Neuro-imaging in the

Diagnosis of Cerebral Lesions” (supervisor: Dap Louw)

Investigator: Genes, metabolism, nutrition and depression with Susan Janse van

Rensburg and Marita Kotze (2011+)

Supervisor: M-student Medical Science (Darnielle Delport) “The development and

application of a polymerase chain reaction (PCR) based assay to determine the

impact of genetic variation in South African patients diagnosed with depression”

Investigator: Facial processing in Schizophrenia with Dana Niehaus et al (2008-

2009)

Investigator: Schizophrenia group with Robin Emsley et al (2007-2008)

Investigator: HIV neuropsychology with Paul Carey et al (2007-2009)

Investigator: Post traumatic stress disorder with Soraya Seedat et al (2004-2006)

Investigator: Social anxiety disorder genetics with Christene Lochner et al (2003-

2005)

Investigator: Differential expression of psychotic features in late bilinguals with

Simone Conradie et al (2008-2012)

Co-supervisor: M-student Linguistics (Tildie Smit) “A grammatical analysis of the

spontaneous language use of schizophrenic versus normal L2 speakers of

English”

Co-supervisor: M-student Linguistics (Janina Theron) “Pragmatic assessment of

schizophrenics' L1 and L2 use: A comparison of three assessment tools”

July 2014

15

Investigator: The use of Thyroid screening tests in Psychiatry (2008-2012)

Supervisor: MMed (Anusha Lachman) “The Clinical Utility and Cost Effectiveness

of Routine Thyroid Screening in Adult Psychiatric Patients Presenting at Stikland

Hospital, Cape Town, South Africa.

Investigator: Depression in brain tumours (2009-2011)

Supervisor: M-student Psychology (Winnie Janse van Rensburg) “The relationship

between depressive symptoms and post-operative subjective pain

perception after third molar surgery”

Investigator: Depression and the influence on acute post operative pain (2011+)

Supervisor: M-student Psychology (Carike Vermaak) in progress

CLINICAL TRIAL EXPERIENCE

N06/08/148: A prospective study of clinical, biological and functional aspects of outcome in

first-episode psychosis. (Phase IV). Designation: Sub-Investigator

M07/04/017: Acute effects of an atypical vs a conventional antipsychotic on brain structure

and function in first-episode psychosis: A voxel-based and functional MRI study. (Phase IV).

Designation: Sub-Investigator

ZM2005/00080/03: A Ten-Week multicenter randomized double blind placebo and active-

controlled parallel group flexible dose study evaluating the efficacy, safety and tolerability of

GSK372475 or Extended release Venlafaxine compared to placebo in adult subjects

diagnosed with Major Depressive Disorder. (Phase III). Designation: Sub-Investigator

D144AC00003: An International, Multicenter, Double-blind, Randomized, Placebo-

controlled, Phase IV Study of the Safety of Lithium versus Placebo as an add on to

July 2014

16

SEROQUEL XR™ (Quetiapine Fumarate) in Adult Patients with Acute Mania. Designation:

Sub-Investigator

H6P-MC-HDAY: A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and

Fluoxetine Combination versus Fluoxetine Only in the Relapse Prevention of Stabilized

Patients with Treatment-Resistant Depression. Designation: Sub-Investigator

3193A1-2005-WW: A 52-Week, 2-Period, Multicenter, Randomized, Double-Blind,

Donepezil-Referenced, Placebo-Controlled, Efficacy, and Safety Study of 3 Dosage Levels

of SAM-531 in Outpatients With Mild to Moderate Alzheimer’s Disease. Designation: Sub-

Investigator

3151A1-3360-WW: A Multicenter, Double-Blind, Placebo-Controlled, Randomized

Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50mg/day of DVS

SR in Adult Outpatient’s With Major Depressive Disorder. Designation: Sub-Investigator

D1050235: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose,

Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of

Bipolar I Depression. Designation: Sub-Investigator

D1050236: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed Flexible-Dose,

Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression. Designation:

Sub-Investigator

D1050256: A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the

Treatment of Bipolar I Depression. Designation: Sub-Investigator

31-07-247: A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to

Evaluate the Efficacy, Safety and Tolerability of an Intramuscular Depot formulation of

Aripiprazole (OPC-1457) as Maintenance Treatment in Patients with Schizophrenia “ASPIRE

EU” (Aripiprazole Intramuscular Depot Program in Schizophrenia) . Designation: Sub-

Investigator

31-07-248: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of

Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia

July 2014

17

“ASPIRE OPEN-LABEL” (Aripiprazole Intramuscular Depot Program in Schizophrenia).


R092670SCH3005: A 24-month, Prospective, Randomized, Active-Controlled, Open-Label,

Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing

Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual with Oral

Antipsychotics Monotherapy in Adults With Schizophrenia. Designation: Sub-Investigator

RISSCH4230: This is an observational, non-interventional registry designed to assess

medication usage patterns and to explore, in clinical routine practice, long-term outcomes

and relevant factors for subject adherence to treatment, in subjects receiving antipsychotic

treatment with risperidone long-acting injectable (RLA) or oral antipsychotics. Six-month

retrospective data and 1-year prospective data will be collected. Designation: Sub-

Investigator

D144AC00003: An International, Multicenter, Double-blind, Randomized, Placebo controlled,

Phase IV Study of the Safety of Lithium versus Placebo as an add on to SEROQUEL XR™

(Quetiapine Fumarate) in Adult Patients with Acute Mania. Designation: Sub-Investigator

RGH-MD-05 11: A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficay of

Cariprazine in the Acute Exacerbation of Schizophrenia. RGH-MD-11 Open Label Extension

Study. Designation: Sub-Investigator

DFI5687: An Eight-Week, Multinational, Multicenter, Double-Blind, Active-And Placebo-

Controlled Clinical Trial Evaluating the Efficacy and Tolerability of Three Fixed Doses of

SSR125543 ( 20mg daily, 50mg Daily, and 100mg daily) in Outpatients with Major

Depressive Disorder. Designation: Sub-Investigator

D4130C00005: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-

Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-

mecamylamine) as an Adjunct to an Antidepressant In Patients with Major Depressive

Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. Designation:

Sub-Investigator

July 2014

18

F1J-MC-HMCK: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in

the Treatment of Children and Adolescents with Major Depressive Disorder. Designation:

Sub-Investigator

P05896: An 8-week, Placebo-Controlled, Double-blind, Randomized, Fixed Dose Efficacy

and Safety Trial of Asenapine in Adolescent Subjects with Schizophrenia. Designation: Sub-

Investigator

P05897: A 26-week, Multi-Center, Open-Label, Flexible Dose, Long-term Safety Trial of

Asenapine in Adolescent Subjects with Schizophrenia. Designation: Sub-Investigator

R092670-SCA-3004: Phase 3b, A Randomized, Double-Blind, Placebo-Controlled, Parallel-

Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With

Schizoaffective Disorder. Designation: Sub-Investigator

H9P-MC-LNBM(b): A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684

Fixed-Dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major

Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Treatment. Designation: Sub-Investigator

D1050298: A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in

Subjects Who Have Completed a Prior Lurasidone Study. Designation: Sub-Investigator

31-10-270: An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole

Intramuscular Depot in Patients with Schizophrenia. Designation: Sub-Investigator

F1J-MC-HMGI: A Double-Blind, Efficacy and Safety Study of Duloxetine versus Placebo in

the Treatment of Children and Adolescents with Generalized Anxiety Disorder. Designation:

Sub- Investigator

C10953/3072: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to

Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as

Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder.

Designation: Sub -Investigator

July 2014

19

C10953/3073: A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to

Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/day) as Adjunctive

Therapy in Adults With Major Depression Associated With Bipolar I Disorder.


C10953/3074: A 6-Month, Open-Label, Flexible-Dosage (150mg to 200mg/day) Extension

Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults

With Major Depression Associated With Bipolar I Disorder. Designation: Sub- Investigator

MEM-MD-91: An Open-Label Study of the Safety and Tolerability of Memantine in Pediatric

Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not

Otherwise Specified (PDD-NOS). Designation: Sub-Investigator

MEM-MD-68: A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the

Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or

Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated

with Memantine. Designation: Sub-Investigator

MEM-MD-69: An Open-Label Extension Study of the Safety and Tolerability of Memantine in

Pediatric Patients with Autism, Asperger’s, Disorder or Pervasive Developmental Disorder

Not Otherwise Specified (PDD-NOS). Designation: Sub-Investigator

SPD489-323: The SPD489-323 Phase 3, Multicenter, Randomized, Double-blind, Parallel-

group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in

Combination with an Antidepressant in the Treatment of Adults with Major Depressive

Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.

Designation: Study Coordinator

SPD489-329: A Phase 3, Open-label, Multicenter, 12-month Extension Safety and

Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of

Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response

Following Treatment With an Antidepressant. Designation: Sub-Investigator

July 2014

20

CN162006: A Multicenter, Randomized, Double-Blind, Active-Controlled Study of the

Efficacy and Safety of Flexibly-Dosed BMS-820836 in patients with Treatment Resistant

Major Depression. Designation: Sub- Investigator

CN162010: A Multicenter, Double-Blind, 58 week Rollover Study to assess the Safety and

Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.


R092670PSY1005: Phase 1, A Single-Dose, Open-Label, Randomized, Parallel-Group

Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate

3-Month Formulation in Subjects with Schizophrenia. Designation: Sub- Investigator

D1050238: A Double-Blind, Placebo-Controlled, Randomized withdrawal Study of

Lurasidone for the Maintenance Treatment of Subjects with Schizophrenia. Designation:

Sub- Investigator

Ly450139: Protocol Amendment Summary H6L-MC-LFAN© Effect of γ-secretase Inhibition

on the Progression of Alzheimer’s Disease: LY450139 versus Placebo. Designation: Sub-

Investigator

CL2-38093-011: Efficacy and safety of S 38093 versus placebo in patients with mild to

moderate Alzheimer’s Disease. Designation: Sub-Investigator

PROFESSIONAL MEMBERSHIP

Health Professions Council of South Africa

South African Society of Psychiatrists

Psychiatric Management Group

South African Medical Association

Medical Protection Society

General Medical Council, UK

July 2014

21

PAST MEMBER (2007-2013)

American Psychiatric Association

World Federation of Biological Psychiatry

Schizophrenia International Research Society

Harp Society of South Africa

LEADERSHIP ACHIEVEMENTS

1993 Students Council, C&N Secondary Girls’ School Oranje

1994-1995 University of the Free State Central Rag Committee

1996 Students Council, Faculty of Medicine, Free State University

1997 Vice-chairperson, Student Council, Faculty of Medicine, Free State

University

2001-2002 Chairperson: Kosmos Garden Project, Psychiatric Complex of the

Free State

2002 Editor “Kosmonews” , Psychiatric Complex of the Free State

Infection Control Committee, Psychiatric Complex of the Free State

Documents

CURRICULUM VITAE - Renata Schoemanrenataschoeman.co.za/wp-content/uploads/2014/07/RenataCV.pdf · July 2014 1 CURRICULUM VITAE PERSONAL DETAILS Name: Renata Schoeman CURRENT POSITION